Who are Menevit anti-oxidant's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Polyethylene glycol / Ascorbic acid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/menevit-anti-oxidant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Menevit anti-oxidant — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Menevit anti-oxidant (Menevit anti-oxidant) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antioxidant supplement. Area: Reproductive Health / Male Infertility.

phase 3 Antioxidant supplement Reproductive Health / Male Infertility Small molecule Live · refreshed every 30 min

Target snapshot

Menevit anti-oxidant (Menevit anti-oxidant) — Repromed. Menevit is an oral antioxidant supplement containing coenzyme Q10, L-carnitine, vitamin E, vitamin C, zinc, folate, and garlic extract designed to improve male fertility by reducing oxidative stress in sperm.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Menevit anti-oxidant TARGET	Menevit anti-oxidant	Repromed	phase 3	Antioxidant supplement
Polyethylene glycol / Ascorbic acid	Polyethylene glycol / Ascorbic acid	Tomas Bata Hospital, Czech Republic	marketed	Osmotic laxative with antioxidant supplement

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antioxidant supplement class)

Repromed · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Menevit anti-oxidant — Competitive Intelligence Brief. https://druglandscape.com/ci/menevit-anti-oxidant. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab